Yuhong Dong
In part 1 and part 2 of this series, we discussed the human papillomavirus (HPV) vaccine and its links to ovarian insu ciency and autoimmune disease.
In part 3, we turn to questions regarding the effectiveness of the vaccine to prevent cervical cancer, and the limitations of relevant clinical trials to detect such a type of effect.
Link to Part 1:
Link to Part 2:
Your donation helps us stand up for healthcare choice!
Canada Health Alliance is volunteer run and 100% supported by the generous donations of those who share our concerns and value our work.
Thank you for your membership application. As soon as your payment has been received your membership will be activated and you will be informed via email.
Thank you.
